Evidence map›Paper›PMID 42470637›Full record

ArticleCell reports2026

PRKCI-ECT2 copy number gain promotes developmental reprogramming and metastatic competence in lung adenocarcinoma.

Duy T Nguyen, Kayleah M Meneses, Cheng Zhang, Luis I Prieto, Capella Weems, Lee Jamieson, Hu Li, Darren J Baker, Andras Khoor, Nicole R Murray and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Duy T NguyenDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Kayleah M MenesesDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Cheng ZhangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Luis I PrietoDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Pediatrics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Capella WeemsDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
Lee JamiesonDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
Hu LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Darren J BakerDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Pediatrics, Mayo Clinic College of Medicine, Rochester, MN, USA; Paul F. Glenn Center for Biology of Aging Research, Mayo Clinic College of Medicine, Rochester, MN, USA; Robert and Arlene Kogod Center on Aging, Mayo Clinic College of Medicine, Rochester, MN, USA.
Andras KhoorDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
Nicole R MurrayDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Verline JustilienDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
Alan P FieldsDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA. Electronic address: fields.alan@mayo.edu.

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
Three-Dimensional Organoid Cultures to Investigate 3q26 Driver Functions in Multiple Lung Cancer Cells of OriginR01CA081436 · NCI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI FIELDS, ALAN P. · 1999 to 2022
$9.9M
Regulation of pten tumor suppressive functions by C-tail phosphorylation.R01CA242023 · NCI · MAYO CLINIC ROCHESTER · PI BAKER, DARREN · 2019 to 2024
$1.8M
Therapeutic targeting of Kras-driven Lung AdenocarcinomaR01CA206367 · NCI · MAYO CLINIC JACKSONVILLE · PI FIELDS, ALAN P. · 2016 to 2020
$1.8M
Investigating cells of origin and oncogenic modifiers of 3q26-driven LUSCR01CA239726 · NCI · MAYO CLINIC JACKSONVILLE · PI FIELDS, ALAN P., JUSTILIEN, VERLINE · 2021 to 2025
$1.8M
NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA081436NCI NIH HHS R01 CA206367NCI NIH HHS R01 CA239726NCI NIH HHS R01 CA242023
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) shows extensive lineage plasticity and early metastatic dissemination, but the oncogenic events that actively drive these processes remain poorly defined. Here, we identify coordinated PRKCI and ECT2 copy number gain, present in approximately 30% of human LUADs, as a driver of developmental reprogramming and metastasis. Using a genetically engineered mouse model that recapitulates PRKCI-ECT2 gain in Kras/Trp53-driven LUAD, we show that elevated PKCι-ECT2 signaling rewires tumor trajectory in a cell-of-origin-dependent manner. Alveolar type II cell-derived tumors dedifferentiate into a distal SOX9

Indexed as

Adenocarcinoma of LungCellular ReprogrammingDNA Copy Number VariationsLung NeoplasmsProtein Kinase CProto-Oncogene ProteinsAnimalsHumansIsoenzymesMiceNeoplasm MetastasisProtein Kinase C-lambdaSignal TransductionSOX9 Transcription FactorECT2 protein, humanIsoenzymesProtein Kinase CProtein Kinase C-lambdaProto-Oncogene ProteinsSOX9 Transcription Factorcopy number gainCP: CancerCP: Developmental biologydevelopmental reprogrammingECT2lineage plasticitylung adenocarcinomametastasisPRKCIsingle-cell RNA sequencingSOX2SOX9

Identifiers

PMID42470637
PMCPMC13563365

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.